AI-driven tools harness ML algorithms to provide insights into anxiety disorders. Supervised ML models, such as logistic ...

Inc. , (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

MeiraGTx's financials show $125 million in cash, but additional funding will be needed within the next 12 months. Click for ...

We also commenced our Phase 2 proof-of-concept study of CYB004 in GAD. I’m proud ... and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

A group of Estonian psychiatrists and civic activists believe that allowing the therapeutic use of currently prohibited ...

Social media’s danger on youth mental health has captured the attention of Texas lawmakers, at times, eclipsing focus on ...

H.C. Wainwright reaffirmed its Buy rating on Cybin Inc. (NYSE:CYBN) with a steady price target of $190.00, significantly above the current trading price of $9.59. With a market capitalization of $192 ...

The nature and the extent of change produced by these various forms of treatment are highly complex ... obsessive-compulsive disorder, or generalized anxiety disorder. Importantly, there is ...

Of more than 2,600 US healthcare workers who participated in a nationwide online panel survey from 2022 to 2023, 26% reported ...